GE Vernova, just over a year into its existence as an independently-traded public company, is riding the artificial ...

Investing.com -- RBC Capital Markets has upgraded its ratings on both Sartorius AG (ETR: SATG) and Sartorius Stedim (EPA: ...

The company raised its full-year 2025 guidance for revenue, net income, and earnings per share. These 10 stocks could mint the next wave of millionaires › Medpace (NASDAQ:MEDP), a clinical contract ...

Funds from operations (Non-GAAP) were $2.33 per share, far exceeding the $0.59 consensus estimate.- Revenue reached $762 ...

Difficulties lie ahead for China, but if it can avoid policy errors, it is likely to emerge stronger in the end ...

Stocks in a coconut-water drink producer jumped in its first day of trading in Hong Kong this week, proving that even in the ...

Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Health-care companies rose sharply on strong earnings. Boston Scientific rallied after the medical-device maker said robust demand for its stents and other cardiology devices generated earnings growth ...

Castle Biosciences' DecisionDx-Melanoma test and Revolution Medicines' elironrasib cancer drug receive FDA Breakthrough ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts ...